Johnson & Johnson today said the Food and Drug Administration agreed to extend the expiration date for its COVID-19 vaccine by six weeks. The move means the J&J vaccine can now be stored for four-and-a-half months, compared with the original authorization of three months, and helps avert the potential, imminent expiration of millions of unused doses.
 
Meanwhile, Moderna formally requested that the FDA expand the emergency use authorization for its COVID-19 vaccine to include individuals between the ages of 12 and 17. Moderna had previously reported phase 2/3 trial results indicating 100% efficacy across this age group against COVID-19 when using the same case definition as in adults.

 

Related News Articles

Headline
The Department of Health and Human Services today announced a $3 billion investment in antiviral treatments for COVID-19, particularly those administered…
Headline
The Centers for Disease Control and Prevention June 11 updated requirements for health care providers participating in the COVID-19 Vaccination Program to…
Headline
The Food and Drug Administration yesterday authorized for emergency use one more batch of drug substance manufactured for the Janssen (Johnson &…
Headline
Rhode Island health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence of…
Headline
Moderna Inc. today announced an agreement with the U.S. government for the purchase of an additional 200 million doses of Moderna’s COVID-19 vaccine,…
Headline
As requested by the AHA, the Centers for Medicare & Medicaid Services yesterday said it will continue to remain flexible in its approach to surveys if a…